Oaktree III Life Sciences

SPAC officer turnover often signals internal readiness for reporting obligations tied to a future combination, but this filing frames the transition as routine sponsorship-aligned succession rather than strategic disruption, particularly because the incoming CFO receives zero personal compensation and relies on standard pre-existing indemnification frameworks. The immediate internal replacement and audit committee chair confirmation suggest governance continuity is being maintained ahead of any potential due diligence or proxy solicitation cycle. Because no merger agreement, target identification, trust drawdown, extension proposal, or shareholder voting notice accompanies this submission, the existing fiduciary timeline and redemption mechanics proceed unadjusted. Investors monitoring whether management intends to seek an extension, renegotiate warrant structures, or accelerate a business combination should monitor subsequent filings, as this submission functionally serves as an administrative continuity record rather than a transactional catalyst.

This is the first annual report post-IPO, providing audited financials, trust account details, and confirmation of the SPAC's status. Key metrics for investors: trust value $193.6M ($10.08/share), cash outside trust $1.357M, deadline October 2026. The filing also discloses the sponsor's substantial ownership (20% on an as-converted basis) and potential conflicts of interest. No change in redemption terms or extension requests. The document is material for tracking the SPAC's progress and financial position.

The filing provides the exact trust balance and revised capital structure required to update per-share redemption metrics and track sponsor equity dilution mechanisms ahead of the fixed liquidation date. The automatic share forfeiture demonstrates standard contractual alignment without triggering sponsor governance actions or search delays. Because the document is strictly a post-IPO capital transaction report, it contains no statements regarding acquisition targets, revenue projections, market sizing, technology roadmaps, strategic partnerships, or executive personnel changes. Management explicitly attributes the pro forma data to internal preparation, notes that the independent registered public accounting firm performed no audit, review, or assurance procedures, and warns investors not to rely on the figures as indicative of historical or future financial positions. The report neither advances nor impedes the target identification timeline.

This filing marks OACC's definitive shift from a pre-IPO blank check vehicle to a capitalized public shell, locking in the trust balance and underwriting fee structure that will directly impact net asset value and redemption economics. Management states that as of October 25, 2024, the company has not identified any business combination target and has conducted no substantive discussions toward a transaction. The stated acquisition strategy requires targets carrying an aggregate fair market value of at least 80% of the trust's net assets (excluding deferred underwriting commissions and taxes on interest) and necessitates obtaining 50% or more of the target's voting securities to satisfy the Investment Company Act of 1940 thresholds. The independent auditor, WithumSmith+Brown PC, issued an unqualified opinion on the October 25 balance sheet, confirming $2,000,000 in operating cash and $81,800 in prepaid expenses offset by $7,583,827 in total liabilities, leaving a shareholders' deficit of $5,502,027. Chief Executive Officer Zaid Pardesi executed the 8-K. Financial notes detail the derivative treatment of the over-allotment liability, valued at $268,690 via a Black-Scholes model using 4.89% volatility, and the allocation of $196,000 to public warrants priced using a Monte Carlo simulation applying 11.7% volatility and a 7.01-year term. Risk disclosures authored by the registrant warn that geopolitical instability from the Russia-Ukraine and Israel-Hamas conflicts could disrupt global capital markets, trigger supply chain interruptions, and hinder the search for viable life sciences targets. The filing attributes all strategic objectives, market outlooks, and procedural mechanics exclusively to management and contractual undertakings, with no operating revenues generated to date and future performance reliant solely on non-operating trust interest and eventual business combination execution.

Positioning by the named entities establishes a substantial passive block without altering governance leverage, given the explicit shared-only authority and control certification. The absence of sole voting or dispositive rights reduces the likelihood of unilateral redemption pressure or trust restructuring demands. The administrative distinction between unit and Class A share CUSIP availability reflects standard settlement timeline synchronization rather than commercial developments. Because the filing contains no operational metrics, strategic declarations, customer commitments, revenue projections, market estimates, technology roadmaps, partnership frameworks, litigation exposures, or executive changes beyond legal signatory titles, investors must monitor subsequent proxy statements, merger definitive agreements, or trust indenture amendments for concrete combination timelines, special meeting schedules, or capital commitment adjustments.

This filing establishes the SPAC's financial foundation for its search period. The trust has a per-share value of $10.69, providing a known redemption baseline for investors. The documents detail critical terms including lock-up periods (Founder Shares: 180 days post-business combination; Private Placement Units: 30 days post-business combination), an underwriting fee structure (including a deferred discount of $0.35/unit paid only upon a business combination from the trust), and that the Sponsor will indemnify the trust against certain third-party claims up to the $10.00 per share minimum. The trust assets can only be used post-deal or for permitted withdrawals (taxes and up to $250k/year in working capital from interest), preserving principal for shareholders.

Investors monitoring capital event timelines and trust preservation must recognize that the 15% redemption cap and the 24-to-36 month extension corridor define the maximum capital retention parameters before mandatory liquidation. The disclosed sponsor economics—founder shares issued at $0.005 per share, fixed monthly administrative withdrawals, and convertible debt structures—create measurable dilution vectors that will directly impact net tangible book value calculations and per-share liquidation thresholds during any future vote.

This filing is the primary disclosure document for OACC's IPO. It establishes the trust value per share at $10.00, the redemption mechanics, and the 24-month deadline for completing a business combination. It details sponsor economics and incentives, including the nominal cost of founder shares ($0.005 per share), which creates significant dilution risk for public shareholders. The document also outlines the company's strategy to target life sciences companies in North America, the UK and Western Europe, leveraging Oaktree's platform, and includes risk factors that investors should consider, including the risk of not finding a target and potential warrant dilution.

This comment suspends the registration’s path to effectiveness until resolved, directly compressing the effective date and extending the SEARCHING phase toward the 2026-10-25 deadline, which shapes the redemption calendar and extension decision window. SEC staff scrutiny over whether transfer restrictions apply to sponsor membership interests rather than just the underlying founder shares signals heightened examination of sponsor liquidity mechanics, influencing investor assessments of long-term alignment and potential secondary sales ahead of de-SPACing.

Investors monitoring sponsor conduct should note the SEC’s explicit flagging of the sponsor’s retained unilateral exit authority, which now carries a documented risk that Oaktree could withdraw from the sponsorship role mid-search, potentially leaving the SPAC without experienced leadership to negotiate or complete a target acquisition. The voting agreement clarification dictates how insider-acquired public shares will be treated at a future business combination vote, directly shaping redemption math and approval thresholds once a target is presented.

Sets the baseline trust value ($10.00 per share), redemption mechanics, and deadline for investors to track. Discloses sponsor’s nominal cost for founder shares, potential dilution, and conflicts of interest. First public disclosure of SPAC terms for OACC; material to investors evaluating IPO participation and future redemption decisions.

Unresolved SEC comments extend the pre-merger preparation timeline, delaying the publication of proxy statements that govern redemption periods, vote thresholds, and extension elections. The voting reconciliation request directly dictates how sponsor-held founder shares and acquired public shares will cast ballots on a business combination, a mechanic that historically determines whether shareholder redemptions activate or remain capped.

This compliance correspondence materially updates the prospectus disclosures governing shareholder economics and sponsor alignment ahead of a target announcement. According to the Registrant, the clarified extension caps, sponsor financial penalties for missed deadlines, and working capital conversion dilution define the timeline risk and capital preservation expectations for public shareholders. The Registrant’s disclosure of prior management track records—specifically historical extension lengths and redemption percentages in Oaktree Acquisition Corp. and Oaktree Acquisition Corp. II—provides a concrete benchmark for evaluating probability of completion versus liquidation outcomes. The Registrant’s note that sponsor warrants may be called for redemption to unlock gains unavailable to retail holders, paired with independent directors receiving sponsor equity rather than traditional compensation, signals concentrated economic incentives. Furthermore, the Registrant’s clarification on extracting trust interest to satisfy the 1% U.S. federal excise tax impacts post-combination liquidity planning. These disclosures inform investors assessing whether to hold, redeem, or purchase based on updated governance, mechanical safeguards, and sponsor conduct parameters before the operating calendar concludes.

The filing explicitly defines the cash preservation rules, the 24-month liquidation clock, and the extension/redemption pathways that dictate when and how public shareholders can exit. It reveals the economic structure that ties sponsor recovery to deal completion, given the nominal $0.005 founder share cost and the $10.00 unit conversion feature on working capital loans, which creates documented incentives to close transactions quickly regardless of target quality.

The SEC staff directly addressed SPAC mechanics relevant to redemption calendars, extension deadlines, and sponsor conduct. The staff requested disclosure of whether limitations exist on extending the combination window beyond 24 months and the consequences to the sponsor if an extension fails. The staff also asked whether the SPAC may withdraw trust interest to pay the recent 1% U.S. federal excise tax that could be imposed on redemptions.

Investors receive the complete capitalization and governance blueprint prior to funds deployment. The prospectus explicitly establishes a $10.00 trust-per-share baseline, clarifying that initial trust allocations are contractually fixed at $10.00 rather than variable. The 24-month deadline creates acute execution pressure, though the amendment-for-extension covenant preserves public shareholder exit options, preventing unilateral term extensions.

What changed: Schedule 13G beneficial ownership report containing an attached Power of Attorney executed by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. The filing introduces no alterations to Oaktree III Life Sciences’ operational or redemption framework. Per the enclosed text, there are zero updates to trust valuations, shareholder approval thresholds, business combination timelines, or sponsor governance clauses. The submission solely updates internal corporate authorization for regulatory filings. Why it matters: For investors monitoring redemption deadlines, trust value preservation, extension votes, or target acquisition progress, this document offers no substantive shift. The entire Power of Attorney merely delegates signing authority for Securities Exchange Act of 1934 filings (specifically Rule 13f-1 or Regulation 13D-G) to the eighteen individuals named in the exhibit. According to the filing, this authorization remains valid until July 16, 2026, supersedes prior delegations dated July 29,2024 and October 1, 2024, and terminates automatically upon cessation of employment or function for any named individual. No assertions regarding target customer bases, projected revenues, addressable market sizing, technological roadmaps, strategic partnerships, active litigation, or executive personnel changes accompany the form, rendering it administratively inert for Merger Arbitrage or SPAC redemption tracking purposes.

What changed: Annual report on Form 10-K for the fiscal year ended December 31, 2025, filed by Oaktree Acquisition Corp. III Life Sciences, a blank-check company (SPAC) still searching for a target. No deal announced, no extension sought, no amendment to trust or charter. Trust value rose to $10.50 per share (from $10.08) due to interest income. Net income was $7.29 million, entirely from interest. The company reported $1.43 million in cash outside trust and working capital of $249k. The auditor's report again includes a going concern qualification due to the mandatory liquidation deadline of October 25, 2026. CEO Zaid Pardesi and board member David A. Berry were added as directors in January and October 2025 respectively. No redemptions occurred; all 19.2 million public shares remain outstanding and redeemable. Why it matters: The filing serves as a status update for a SPAC with 16 months left before mandatory liquidation. Trust value per share is $10.50, above the $10.00 IPO price, giving shareholders a cushion. The company's cash burn ($422k in operating cash flow) and thin working capital ($249k) raise liquidity risk. The ongoing going concern qualification signals the clock is ticking. New directors (Pardesi as CEO/board; Berry as independent director with biotech/SPAC experience) may indicate deal activity is being ramped up. No target is identified, but the language about a 'large backlog' of life sciences companies suggests the search continues. Investors tracking redemption risk should note the trust is fully intact and no shareholder vote has been called.

What changed: A Schedule 13G/A amendment, classified as a routine regulatory compliance exhibit reporting changes in beneficial ownership. Barclays PLC filed the amendment to update its beneficial ownership disclosures. The provided excerpt attributes no specific share quantities, percentage thresholds, acquisition dates, or transaction prices to Barclays PLC. Consequently, the filing discloses nothing bearing on Oaktree III Life Sciences’ October 25, 2026 combination deadline, the reported $10.69 per share trust amount, redemption mechanics, extension voting processes, target deal progress, or sponsor conduct. Why it matters: The Schedule 13G/A format inherently tracks institutional position shifts that cross or adjust holdings relative to the five percent beneficial ownership reporting line. For investors tracking Oaktree III Life Sciences, Barclays PLC’s updated filing refreshes the known institutional register but carries no mechanical influence over redemption windows, trust maintenance, or business combination timelines. Beyond identifying the holder, the document contains zero statements regarding customers, revenue streams, market size, corporate strategy, proprietary technology, partnership arrangements, litigation exposure, or personnel rosters.

What changed: 10-Q (Quarterly Report). This filing is a routine quarterly report for the period ended September 30, 2025. It reports on the continuing search for a business combination target, financial results including net income of $1,966,742 for the quarter and $5,499,876 for the nine-month period, and trust account value growing to $199,769,089 (from $193,579,022 at year-end 2024) at a redemption value of $10.41 per share. The document discloses two subsequent events: On October 17, 2025, David A. Berry, MD, PhD, was appointed as an independent Class II director. On October 29, 2025, Thomas Sweeney resigned as CFO; George A. Martinez was appointed as the new CFO, effective immediately. The report reiterates a going concern qualification and pending deadline of October 25, 2026. Why it matters: The trust value per share has increased to $10.41 from $10.08, providing a growing floor for redemption. The CFO change is a material operational shift, but the resignation was stated as not due to disagreements with management. No business combination agreement has been announced and the deadline remains unchanged, reinforcing the time pressure on the sponsor.

What changed: A Form 8-K current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically detailing an executive departure and appointment under Item 5.02. Chief Executive Officer Zaid Pardesi reported that Thomas Sweeney resigned as Chief Financial Officer effective October 29, 2025, to pursue other professional opportunities, and explicitly stated there were no disagreements with the Board or management. The Board simultaneously appointed George A. Martinez as the new Chief Financial Officer (principal accounting and principal financial officer) effective immediately. Mr. Pardesi attributed to the filing that Mr. Martinez currently serves as a Senior Vice President in Oaktree Capital Management, L.P.’s finance organization, previously worked at Ernst & Young from 2013 to 2024, holds California CPA licensure, and earned a Master of Accounting from the University of Southern California and a Bachelor of Arts from Occidental College. Mr. Pardesi disclosed that Mr. Martinez will receive zero compensation from the Company, has signed no employment agreement, and will execute indemnification and letter agreements on terms identical to those executed at the initial public offering. Why it matters: This filing makes no adjustments to the redemption calendar, trust account mechanics, or business combination deadline. The trust value per share remains $10.69, the warrant exercise price remains $11.50, and the liquidation deadline remains October 25, 2026. There is no announcement of a target, extension proposal, or change to shareholder voting rights. Regarding sponsor conduct, the appointment maintains administrative continuity through an existing Oaktree affiliate rather than hiring externally, which avoids dilution and preserves cash for potential deal expenses while the entity searches. For investors tracking the path to a de-SPAC transaction, this confirms governance stability but provides no progression toward a merger or adjustment to the redemption framework prior to the October 2026 deadline.

What changed: SEC Form 3, an initial statement of beneficial ownership that functions as a routine compliance exhibit. The filing discloses zero non-derivative transactions or equity holdings for Chief Financial Officer George Arthur Martinez. Consequently, there are no updates to the $10.69 per share trust value, the October 25, 2026 termination deadline, any active business combination, or sponsor trading conduct. Why it matters: A Form 3 with no reported public-equity positions indicates the executive currently holds no registrable shares or warrants from the IPO or promote that require disclosure in this filing. For investors monitoring redemption pressure, extension vote thresholds, or insider capital commitment, this submission confirms no new public-market accumulation or liquidation by senior leadership. The text contains no attributed claims regarding target search progress, revenue forecasts, technology licensing, customer contracts, partnership discussions, litigation, or material personnel changes. Without accompanying amendments or S-4/proxy filings, the document does not advance the SEARCHING phase nor alter the contractual mechanics governing shareholder redemptions or trust distribution schedules.

What changed: SEC Form 3 — insider ownership report. Director David A. Berry filed a routine Form 3 stating he reported no non-derivative transactions or holdings. No equity positions were acquired, disposed of, pledged, or established during the reporting window. The SPAC’s search parameters, board composition, and corporate governance mechanics remain static. Why it matters: This submission contains zero statements or data points regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel changes beyond the director’s name. It is an administrative compliance record that indicates no alteration in sponsor conduct, insider alignment, or capital deployment. Investors tracking the redemption calendar, trust distribution schedule, extension windows, or merger negotiations should treat it as procedurally neutral; it conveys no actionable signal and requires no portfolio adjustment.

What changed: Form 8-K Current Report itemizing the appointment of a new independent director, committee placements, independence certifications, director compensation structure, and expected governance agreements. Per the Board of Directors of Oaktree Acquisition Corp. III Life Sciences, on October 17, 2025 the company appointed David A. Berry, MD, PhD, as a Class II independent director serving until a successor is qualified or he resigns/removes himself. The Board assigned Dr. Berry to the audit, nominating, and compensation committees and certified that he satisfies Nasdaq independence listing standards and the Rule 10A-3 definition of an independent director. The Board stated Dr. Berry will receive $0 in compensation for these director services. Consistent with disclosures in the Company’s Annual Report on Form 10-K filed March 27, 2025, the Board expects Dr. Berry to invest in a non-controlling minority position in Oaktree Acquisition Holdings III LS, LLC, matching arrangements for other independent directors. Dr. Berry is also expected to sign Letter Agreements and Indemnity Agreements on identical terms to those executed by directors and officers at the initial public offering. The filing confirms no family relationships exist between Dr. Berry and current management. The report was signed by Chief Executive Officer Zaid Pardesi. This filing leaves the stated $10.69 per-share trust value and the October 25, 2026 redemption deadline unchanged and does not trigger any extension vote, trust withdrawal, or redemption window adjustment. Why it matters: For shareholders monitoring a search-phase SPAC, this update refreshes board capacity without moving the redemption calendar or touching the trust account. Adding a director with extensive public-market operational experience across biotechnology and health-tech ventures (Valo Health, Omega Therapeutics, Seres Therapeutics, Axcella Health, Evelo Biosciences) and prior venture-stage roles at Flagship Pioneering and Averin Capital expands the board’s industry network ahead of the October 2026 deadline. The zero-compensation structure and standard indemnity/letter agreements keep governance expenses neutral, while the anticipated minority co-investment in the sponsor vehicle aligns independent directors with existing economics without encumbering the public trust. No target identification, LOI, merger discussion, or deal financing is reported, meaning the entity remains formally in search mode with the trust balance intact and redemption rights unaltered.

What changed: Quarterly report on Form 10-Q for the quarter ended June 30, 2025 (routine SEC compliance filing by a blank-check SPAC in searching status). The trust account value increased from $193,579,022 ($10.08 per share) at Dec 31, 2024 to $197,576,768 ($10.29 per share) at June 30, 2025, driven by $4,247,746 in interest income. Cash outside trust rose from $1,357,044 to $1,385,359. Working capital decreased from $831,002 to $441,907. The Company recorded net income of $3,533,134 for H1 2025. On June 3, 2025, CFO Courtney Conigliaro resigned and was replaced by Thomas Sweeney. No business combination target has been selected, and no extension has been proposed. The deferred underwriting fee remains $6,719,660 and deferred legal fees $299,088. The sponsor forfeited 231,492 founder shares upon the partial over-allotment exercise in October 2024, leaving 4,799,758 Class B shares outstanding. Why it matters: The trust value per share has grown to $10.29, offering a modest premium over the $10.00 IPO trust for redeeming shareholders. The deadline is still October 25, 2026, leaving ample time to find a target. The CFO resignation is an administrative change but could signal a shift in deal-preparation focus. The lack of any announced target or letter of intent confirms the SPAC remains in early search stage. The Company has sufficient liquidity ($1.4M cash plus $250k annual trust withdrawals) to continue operations without additional financing before a business combination.

What changed: A Schedule 13G/A amendment containing two appended Powers of Attorney executed by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. Both Goldman Sachs entities replaced prior Powers of Attorney dated July 29, 2024 and October 1, 2024 with new instruments executed on July 16, 2025. The updated documents revise the roster of designated attorneys-in-fact but preserve identical operative clauses: unilateral revocation rights, a July 16, 2026 expiration, New York governing law, and delegated authority to sign filings under Rule 13f-1 or Regulation 13D-G. These adjustments reflect routine internal staffing transitions and do not modify beneficial ownership percentages, voting directives, or investment discretion. Why it matters: The filing bears no relation to OACC’s merger timeline, redemption procedures, trust distribution mechanics, or sponsor governance protocols. It contains zero commercial assertions regarding target pipeline development, customer acquisition, revenue realization, market capitalization, technological milestones, strategic alliances, contingent liabilities, or executive turnover. All stated provisions are self-referential compliance delegations made exclusively by the two institutional holder entities listed on the form. Because the document discloses only administrative signing authority for periodic ownership reporting, it provides no signal regarding potential extension resolutions, tender offer scheduling, or deal conviction, and therefore holds no material relevance for transaction or liquidity tracking.